Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Revenue of Milestone Pharmaceuticals Inc. (MIST)
Revenue in 2023 (TTM): $1000 K
According to Milestone Pharmaceuticals Inc.'s latest financial reports the company's current revenue (TTM) is $1000 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Milestone Pharmaceuticals Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1000 K | $1000 K | $-56,845,000 | $-59,685,000 | $-59,685,000 |
| 2022 | $5 M | $4.52 M | $-58,364,000 | $-58,388,000 | $-57,134,000 |
| 2021 | $15 M | $15 M | $-42,980,000 | $-42,853,000 | $-42,633,000 |
| 2020 | $ | $-376,000 | $-50,710,000 | $-49,984,000 | $-49,967,000 |
| 2019 | $ | $-236,000 | $-57,881,000 | $-55,285,000 | $-55,229,000 |
| 2018 | $ | $-10,000 | $-23,358,000 | $-23,111,000 | $-23,185,000 |
| 2017 | $ | $-8,000 | $-8,260,000 | $-8,082,000 | $-8,086,000 |